Aprea Therapeutics Net Income
| APRE Stock | USD 0.75 0.05 6.25% |
As of the 3rd of February, Aprea Therapeutics shows the Mean Deviation of 3.69, standard deviation of 6.45, and Risk Adjusted Performance of (0.08). Aprea Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aprea Therapeutics information ratio and potential upside to decide if Aprea Therapeutics is priced correctly, providing market reflects its regular price of 0.75 per share. As Aprea Therapeutics is a penny stock we also strongly suggest to validate its jensen alpha numbers.
Aprea Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Revenue | Earnings Share (2.12) | Quarterly Revenue Growth (0.99) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.7 M | -12.2 M | |
| Net Loss | -101.4 M | -96.3 M | |
| Net Loss | -11.7 M | -12.2 M | |
| Net Loss | (2.70) | (2.84) | |
| Net Income Per E B T | 1.13 | 1.10 |
Aprea | Net Income | Build AI portfolio with Aprea Stock |
Analyzing Aprea Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Aprea Therapeutics's current valuation and future prospects.
Latest Aprea Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aprea Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aprea Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aprea Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aprea Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aprea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.96 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aprea Net Income Regression Statistics
| Arithmetic Mean | (21,358,084) | |
| Coefficient Of Variation | (127.16) | |
| Mean Deviation | 17,146,221 | |
| Median | (15,190,250) | |
| Standard Deviation | 27,159,304 | |
| Sample Variance | 737.6T | |
| Range | 112.4M | |
| R-Value | (0.38) | |
| Mean Square Error | 671.7T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | (2,057,265) | |
| Total Sum of Squares | 11802T |
Aprea Net Income History
Other Fundumenentals of Aprea Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Aprea Therapeutics Net Income component correlations
Aprea Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aprea Therapeutics is extremely important. It helps to project a fair market value of Aprea Stock properly, considering its historical fundamentals such as Net Income. Since Aprea Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aprea Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aprea Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Aprea diversify its offerings? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aprea Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Understanding Aprea Therapeutics requires distinguishing between market price and book value, where the latter reflects Aprea's accounting equity. The concept of intrinsic value—what Aprea Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aprea Therapeutics' price substantially above or below its fundamental value.
Understanding that Aprea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aprea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aprea Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Aprea Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aprea Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aprea Therapeutics.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Aprea Therapeutics on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Aprea Therapeutics or generate 0.0% return on investment in Aprea Therapeutics over 90 days. Aprea Therapeutics is related to or competes with Acurx Pharmaceuticals, Biocardia, Kiora Pharmaceuticals, Galecto, Adial Pharmaceuticals, In8bio, and Creative Medical. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel ca... More
Aprea Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aprea Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aprea Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 27.77 | |||
| Value At Risk | (8.43) | |||
| Potential Upside | 4.4 |
Aprea Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aprea Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aprea Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aprea Therapeutics historical prices to predict the future Aprea Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.50) |
Aprea Therapeutics February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 3.69 | |||
| Coefficient Of Variation | (839.97) | |||
| Standard Deviation | 6.45 | |||
| Variance | 41.58 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 27.77 | |||
| Value At Risk | (8.43) | |||
| Potential Upside | 4.4 | |||
| Skewness | 2.05 | |||
| Kurtosis | 16.49 |
Aprea Therapeutics Backtested Returns
Aprea Therapeutics secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of risk over the last 3 months. Aprea Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aprea Therapeutics' Risk Adjusted Performance of (0.08), mean deviation of 3.69, and Standard Deviation of 6.45 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.55, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aprea Therapeutics will likely underperform. At this point, Aprea Therapeutics has a negative expected return of -0.71%. Please make sure to confirm Aprea Therapeutics' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Aprea Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.74 |
Good predictability
Aprea Therapeutics has good predictability. Overlapping area represents the amount of predictability between Aprea Therapeutics time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aprea Therapeutics price movement. The serial correlation of 0.74 indicates that around 74.0% of current Aprea Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.74 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aprea Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aprea Therapeutics reported net income of (12.96 Million). This is 103.8% lower than that of the Biotechnology sector and 118.5% lower than that of the Health Care industry. The net income for all United States stocks is 102.27% higher than that of the company.
Aprea Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aprea Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aprea Therapeutics could also be used in its relative valuation, which is a method of valuing Aprea Therapeutics by comparing valuation metrics of similar companies.Aprea Therapeutics is currently under evaluation in net income category among its peers.
Aprea Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aprea Therapeutics from analyzing Aprea Therapeutics' financial statements. These drivers represent accounts that assess Aprea Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aprea Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 61.1M | 548.5K | 17.0M | 18.1M | 20.8M | 19.8M | |
| Enterprise Value | 8.2M | (28.2M) | (4.6M) | (4.7M) | (5.4M) | (5.2M) |
Aprea Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aprea Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Aprea Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aprea Therapeutics' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 14.5 K | Hightower Advisors, Llc | 2025-06-30 | 13.9 K | Blackrock Inc | 2025-06-30 | 8.5 K | Bank Of America Corp | 2025-06-30 | 4.9 K | Tower Research Capital Llc | 2025-06-30 | 3 K | Mb, Levis & Associates, Llc | 2025-06-30 | 806 | Group One Trading, Lp | 2025-06-30 | 577 | Fmr Inc | 2025-06-30 | 501 | Advisor Group Holdings, Inc. | 2025-06-30 | 400 | Aigh Capital Management, Llc | 2025-06-30 | 539.3 K | Sio Capital Management, Llc | 2025-06-30 | 279.4 K |
Aprea Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | (9.59 M) | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 19.54 % | ||||
| Shares Owned By Institutions | 21.59 % | ||||
| Number Of Shares Shorted | 35.95 K | ||||
| Price To Earning | (9.54) X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 11.40 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | (7.91 M) | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (12.96 M) | ||||
| Cash And Equivalents | 39.06 M | ||||
| Cash Per Share | 1.67 X | ||||
| Total Debt | 4.67 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.45 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (13.56 M) | ||||
| Short Ratio | 0.53 X | ||||
| Earnings Per Share | (2.12) X | ||||
| Target Price | 6.67 | ||||
| Beta | 1.61 | ||||
| Market Capitalization | 5.57 M | ||||
| Total Asset | 23.98 M | ||||
| Retained Earnings | (321.04 M) | ||||
| Working Capital | 20.22 M | ||||
| Current Asset | 39.28 M | ||||
| Current Liabilities | 5.96 M | ||||
| Net Asset | 23.98 M |
About Aprea Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aprea Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aprea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aprea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:Check out For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Aprea diversify its offerings? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aprea Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Understanding Aprea Therapeutics requires distinguishing between market price and book value, where the latter reflects Aprea's accounting equity. The concept of intrinsic value—what Aprea Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aprea Therapeutics' price substantially above or below its fundamental value.
Understanding that Aprea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aprea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aprea Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.